Urinary Proteomics Analysis for Sepsis and Prognosis

Urinary Proteomics Analysis for Sepsis Identification and Its Prognosis in Sepsis Patient With iTRAQ Labeling and and LC-MS/MS

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01493492

Enrollment

Registered

2011-12-16

Start date

2010-05-31

Completion date

2012-01-31

Last updated

2011-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, SIRS

Keywords

proteomics,urinary,sepsis,prognosis

Brief summary

As a noninvasive examination, urinary proteomics is a very useful tool to identify renal disease. The purpose of the present study was to find differential proteins among patient with SIRS and sepsis(included survivors and non-survivors), and to screen potential biomarkers for the early diagnosis of sepsis and its prognosis. Urinary proteins were identified by iTRAQ labeling and LC-MS/MS. The bioinformatics analysis was performed with the Mascot software and the International Protein Index (IPI) and the Gene Ontology (GO) Database and KEGG pathway Database. The differentially expressed proteins were verified by Western blot by another sample collected from clinical.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male and female aged 18 years old and over; * clinically confirmed infection; * fulfilled at least two criteria of systemic inflammatory response syndrome * (a) core temperature higher than 38 °C or lower than 36 °C * (b)respiratory rate above 20/min, or PCO2 below 32 mmHg * (c) pulse rate above 90/min, and * (d) white blood cell count greater than 12,000/μl or lower than \< 4,000/μl or less than 10% of bands.

Exclusion criteria

* younger than 18 years of age; * acquired immunodeficiency syndrome; * reduced polymorphonuclear granulocyte counts (\< 500 μL-1); * died within 24h after admission into the ICU, or refused to participate in the study, or declined treatment during the period of observation.

Design outcomes

Primary

Measure	Time frame	Description
Survival status	28days after admited in ICU	The survival time of patients more than 28days is defined as survival. The survival time of patients less than 28days is defined as death

Countries

China

Contacts

Primary ContactLongxiang Su, MD

slx77@163.com15620952878

Outcome results